Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.
You may also be interested in...
Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.
The MD Anderson Cancer Center administrator's lack of significant government administration experience may inspire questions during the confirmation process.
Senior Biomedical Research Service expansion, used to attract elite scientists to federal service, may not be implemented until late 2019; FDA also may have a candidate for OND director.